You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AMD, poor responders, aflibercept, brolucizumab

Showing 1 - 25 of 9,652
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Age-Related Macular Degeneration Trial in Hong Kong (Brolucizumab, Aflibercept)

Recruiting
  • Age-Related Macular Degeneration
  • Hong Kong, Hong Kong
    Grantham Hospital
Jan 25, 2023

Wet Age-related Macular Degeneration Trial in Bern (Aflibercept, Brolucizumab, early treat and extend (T&E))

Enrolling by invitation
  • Wet Age-related Macular Degeneration
  • Bern, Switzerland
    Berner Augenklinik am Lindenhofspital
May 13, 2022

Neovascular Age-related Macular Degeneration Trial in Binningen (Brolucizumab 6 mg solution for intravitreal injection)

Terminated
  • Neovascular Age-related Macular Degeneration
  • Brolucizumab 6 mg solution for intravitreal injection
  • Binningen, Baselland, Switzerland
    Vista Klinik
Dec 8, 2021

Neovascular Age-Related Macular Degeneration Trial in China (Brolucizumab 6mg, Aflibercept 2 mg)

Recruiting
  • Neovascular Age-Related Macular Degeneration
  • Brolucizumab 6mg
  • Aflibercept 2 mg
  • Guangzhou, Guangdong, China
  • +30 more
Jan 20, 2023

Ocular Adverse Events in Neovascular Age-related Macular

Completed
  • Age-related Macular Degeneration (AMD)
  • Aflibercept
  • +2 more
  • East Hanover, New Jersey
    Novartis Investigative Site
Dec 15, 2021

Ocular Adverse Events in Neovascular Agerelated Macular

Completed
  • Age-related Macular Degeneration (AMD)
  • Aflibercept
  • +2 more
  • East Hanover, New Jersey
    Novartis Investigative Site
Dec 15, 2021

Neovascular Age-related Macular Degeneration Trial in Worldwide (brolucizumab)

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Huntington Beach, California
  • +59 more
Jan 20, 2023

Neovascular Age-related Macular Degeneration

Completed
  • Age-related Macular Degeneration (AMD)
  • East Hanover, New Jersey
    Novartis Investigative Site
Dec 15, 2021

Age-related Macular Degeneration (AMD) Trial (brolucizumab)

Withdrawn
  • Age-related Macular Degeneration (AMD)
  • (no location specified)
Sep 21, 2021

Neovascular Age-related Macular Degeneration

Completed
  • Age-related Macular Degeneration (AMD)
  • East Hanover, New Jersey
    Novartis Pharmaceuticals
Oct 19, 2021

Number of Patient Eyes That Remained on or Switched to Anti-VEGF

Completed
  • Age-related Macular Degeneration (AMD)
  • East Hanover, New Jersey
    Novartis Investigational site
Oct 6, 2021

Exudative Age-related Macular Degeneration Trial (intravitreal injection)

Completed
  • Exudative Age-related Macular Degeneration
  • intravitreal injection
  • (no location specified)
Apr 19, 2022

Age-Related Macular Degeneration, Pachychoroid Neovasculopathy Trial (Brolucizumab Injection [Beovu])

Not yet recruiting
  • Age-Related Macular Degeneration
  • Pachychoroid Neovasculopathy
  • Brolucizumab Injection [Beovu]
  • (no location specified)
Dec 21, 2022

Age-related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration Trial in Germany, Switzerland (Brolucizumab)

Recruiting
  • Age-related Macular Degeneration
  • +5 more
  • Brolucizumab
  • Regensburg, Bavaria, Germany
  • +32 more
Jan 20, 2023

Data of Intravitreal Aflibercept Injection in Patients of Wet

Completed
  • Wet Age-related Macular Degeneration
  • Aflibercept (Eylea, BAY86-5321)
  • Multiple Locations, India
    Many Locations
Feb 2, 2023

Diabetic Macular Edema Trial in China (Brolucizumab, Aflibercept)

Active, not recruiting
  • Diabetic Macular Edema
  • Guangzhou, Guangdong, China
  • +23 more
Jan 20, 2023

Following Intensive Anti-VEGF Therapy in Wet AMD

Completed
  • Age-Related Macular Degeneration
  • Budapest, Hungary
  • +1 more
Dec 28, 2022

Branch Retinal Vein Occlusion Trial in Worldwide (Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection)

Terminated
Has Results
  • Branch Retinal Vein Occlusion
  • Brolucizumab 6 mg
  • +2 more
  • Phoenix, Arizona
  • +101 more
Jan 27, 2023

Single Injection of Faricimab for nAMD With Persisting Fluid

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Glostrup, Denmark
    Miklos Schneider
Nov 3, 2023

Wet Macular Degeneration Trial in Prague (Aflibercept 40 MG/ML [Eylea], Brolucizumab-Dbll 120 MG/ML [Beovu], Ranibizumab 6 MG/ML

Withdrawn
  • Wet Macular Degeneration
  • Aflibercept 40 MG/ML [Eylea]
  • +2 more
  • Prague, Czechia
    Department of Ophthalmology, Faculty hospital Kralovske Vinohrad
Aug 7, 2022

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Recruiting
  • Polypoidal Choroidal Vasculopathy
  • +2 more
  • Intravitreal aflibercept injection
  • Seoul, Korea, Republic of
    Jae Hui Kim
Dec 20, 2022

Macular Degeneration, Wet Macular Degeneration Trial in La Jolla (Intravitreal aflibercept injection)

Completed
Has Results
  • Macular Degeneration
  • Wet Macular Degeneration
  • Intravitreal aflibercept injection
  • La Jolla, California
    Shiley Eye Center
Mar 23, 2021

Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization Trial (Brolucizumab ophthalmic solution, Aflibercept

Completed
Has Results
  • Neovascular Age-Related Macular Degeneration
  • Choroidal Neovascularization
  • Brolucizumab ophthalmic solution
  • Aflibercept ophthalmic solution
  • (no location specified)
Sep 9, 2020

Exudative Macular Degeneration, Wet Age-related Macular Degeneration Trial in Iowa City (Doxycycline Hyclate, Placebo)

Recruiting
  • Exudative Macular Degeneration
  • Wet Age-related Macular Degeneration
  • Doxycycline Hyclate
  • Placebo
  • Iowa City, Iowa
    University of Iowa Hospitals & Clinics Department of Ophthalmolo
Apr 5, 2022

Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)

Active, not recruiting
  • Wet Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • ADVM-022
  • Bakersfield, California
  • +10 more
Mar 21, 2022